ADCendo is a biotech company founded in Copenhagen in 2017, focused on the development of novel targeted therapies in the form of antibody-drug conjugates (ADCs).
ADCendo was spun out of The Finsen Laboratory of Rigshospitalet and the University of Copenhagen, based on obtaining a worldwide exclusive license to explore and commercialize certain inventions, made by the founders during their assignments at the Finsen Laboratory, relating to ADCs directed at novel targets. Inventions, which are based on decades of extensive research on the role of this particular receptor in cancer, as part of the laboratory’s basic research program.
The company is currently a resident Creation House stage incubation company with Bioinnovation Institute (BII) in Copenhagen. See more via https://bioinnovationinstitute.com/
The company name, ADCendo, reflects our particular focus on development of antibody-drug conjugates (ADCs) against cancer cell receptors with specialized endocytic properties.